The Effect of Mesna on Plasma Total Homocysteine Concentration in Hemodialysis Patients

American Journal of Kidney Diseases

Volumn 49, Issue 1, 2007, Pages 109-117

  Urquhart, Bradley L ^a   Freeman, David J ^a   Spence, J David ^a   House, Andrew A ^a  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

atherosclerosis; cardiovascular disease; hemodialysis (HD); Homocysteine; mesna

Indexed keywords

ALBUMIN; DISULFIDE; HOMOCYSTEINE; MESNA; TAURINE; VITAMIN;

ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; ASSAY; ATHEROSCLEROSIS; BLOOD SAMPLING; CANADA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISULFIDE BOND; DRUG EFFECT; FEMALE; HEMODIALYSIS; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FAILURE; MALE; PLASMA; PROTEIN BINDING; THIOL EXCHANGE TEST; VITAMIN SUPPLEMENTATION;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HOMOCYSTEINE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MESNA; MIDDLE AGED; PILOT PROJECTS; RENAL DIALYSIS;

EID: 33845472466     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ajkd.2006.10.002     Document Type: Article

References (46)

1. Finkelstein J.D. The metabolism of homocysteine: Pathways and regulation. Eur J Pediatr 157 2 (1998) S40-S44
2. Mosharov E., Cranford M.R., and Banerjee R. The quantitatively important relationship between homocysteine metabolism and glutathione synthesis by the transsulfuration pathway and its regulation by redox changes. Biochemistry 39 (2000) 13005-13011
3. Selhub J. Homocysteine metabolism. Annu Rev Nutr 19 (1999) 217-246
4. Mudd S.H., Finkelstein J.D., Refsum H., et al. Homocysteine and its disulfide derivatives: A suggested consensus terminology. Arterioscler Thromb Vasc Biol 20 (2000) 1704-1706
5. Mansoor M.A., Svardal A.M., and Ueland P.M. Determination of the in vivo redox status of cysteine, cysteinylglycine, homocysteine, and glutathione in human plasma. Anal Biochem 200 (1992) 218-229
6. Chao C.L., Tsai H.H., Lee C.M., et al. The graded effect of hyperhomocysteinemia on the severity and extent of coronary atherosclerosis. Atherosclerosis 147 (1999) 379-386
7. Graham I.M., Daly L.E., Refsum H.M., et al., The European Concerted Action Project. Plasma homocysteine as a risk factor for vascular disease. JAMA 277 (1997) 1775-1781
8. Matetzky S., Freimark D., Ben Ami S., et al. Association of elevated homocysteine levels with a higher risk of recurrent coronary events and mortality in patients with acute myocardial infarction. Arch Intern Med 163 (2003) 1933-1937
9. Stanger O., Weger M., Renner W., and Konetschny R. Vascular dysfunction in hyperhomocyst(e)inemia. Implications for atherothrombotic disease. Clin Chem Lab Med 39 (2001) 725-733
10. Vasan R.S., Beiser A., D'Agostino R.B., et al. Plasma homocysteine and risk for congestive heart failure in adults without prior myocardial infarction. JAMA 289 (2003) 1251-1257
11. Wald D.S., Law M., and Morris J.K. Homocysteine and cardiovascular disease: Evidence on causality from a meta-analysis. BMJ 325 (2002) 1202-1206
12. Wald D.S., Law M., and Morris J.K. The dose-response relation between serum homocysteine and cardiovascular disease: Implications for treatment and screening. Eur J Cardiovasc Prev Rehabil 11 (2004) 250-253
13. Nygard O., Nordrehaug J.E., Refsum H., Ueland P.M., Farstad M., and Vollset S.E. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 337 (1997) 230-236
14. Ubbink J.B., Vermaak W.J., van der M.A., and Becker P.J. Vitamin B-12, vitamin B-6, and folate nutritional status in men with hyperhomocysteinemia. Am J Clin Nutr 57 (1993) 47-53
15. Ubbink J.B., Vermaak W.J., van der M.A., Becker P.J., Delport R., and Potgieter H.C. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 124 (1994) 1927-1933
16. House A.A., and Donnelly J.G. Effect of multivitamins on plasma homocysteine and folate levels in patients on hemodialysis. ASAIO J 45 (1999) 94-97
17. Bostom A.G., Shemin D., Nadeau M.R., et al. Short term betaine therapy fails to lower elevated fasting total plasma homocysteine concentrations in hemodialysis patients maintained on chronic folic acid supplementation. Atherosclerosis 113 (1995) 129-132
18. Bostom A.G., Shemin D., Lapane K.L., et al. High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 49 (1996) 147-152
19. Elian K.M., and Hoffer L.J. Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease. Metabolism 51 (2002) 881-886
20. Spence J.D., Cordy P., Kortas C., and Freeman D. Effect of usual doses of folate supplementation on elevated plasma homocyst(e)ine in hemodialysis patients: No difference between 1 and 5 mg daily. Am J Nephrol 19 (1999) 405-410
21. House A.A., Wells G.A., Donnelly J.G., Nadler S.P., and Hebert P.C. Randomized trial of high-flux vs low-flux haemodialysis: Effects on homocysteine and lipids. Nephrol Dial Transplant 15 (2000) 1029-1034
22. Vriese A.S., Langlois M., Bernard D., et al. Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients. Nephrol Dial Transplant 18 (2003) 2596-2600
23. Bonaa K.H., Njolstad I., Ueland P.M., et al. Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med 354 (2006) 1578-1588
24. Lonn E., Yusuf S., Arnold M.J., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 354 (2006) 1567-1577
25. Toole J.F., Malinow M.R., Chambless L.E., et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA 291 (2004) 565-575
26. Wrone E.M., Hornberger J.M., Zehnder J.L., McCann L.M., Coplon N.S., and Fortmann S.P. Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease. J Am Soc Nephrol 15 (2004) 420-426
27. Loscalzo J. Homocysteine trials-Clear outcomes for complex reasons. N Engl J Med 354 (2006) 1629-1632
28. Sengupta S., Chen H., Togawa T., et al. Albumin thiolate anion is an intermediate in the formation of albumin-S-S-homocysteine. J Biol Chem 276 (2001) 30111-30117
29. Sengupta S., Wehbe C., Majors A.K., Ketterer M.E., DiBello P.M., and Jacobsen D.W. Relative roles of albumin and ceruloplasmin in the formation of homocystine, homocysteine-cysteine-mixed disulfide, and cystine in circulation. J Biol Chem 276 (2001) 46896-46904
30. Scholze A., Rinder C., Beige J., Riezler R., Zidek W., and Tepel M. Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure. Circulation 109 (2004) 369-374
31. House A.A., Eliasziw M., Urquhart B.L., Freeman D.J., and Spence J.D. Dimercaptosuccinic acid for the treatment of hyperhomocysteinemia in hemodialysis patients: A placebo-controlled, double-blind, randomized trial. Am J Kidney Dis 44 (2004) 689-694
32. Urquhart B.L., House A.A., Cutler M.J., Spence J.D., and Freeman D.J. Thiol exchange: An in vitro assay that predicts the efficacy of novel homocysteine lowering therapies. J Pharm Sci 95 (2006) 1742-1750
33. Lauterburg B.H., Nguyen T., Hartmann B., Junker E., Kupfer A., and Cerny T. Depletion of total cysteine, glutathione, and homocysteine in plasma by ifosfamide/mesna therapy. Cancer Chemother Pharmacol 35 (1994) 132-136
34. Pendyala L., Creaven P.J., Schwartz G., et al. Intravenous ifosfamide/mesna is associated with depletion of plasma thiols without depletion of leukocyte glutathione. Clin Cancer Res 6 (2000) 1314-1321
35. Stofer-Vogel B., Cerny T., Kupfer A., Junker E., and Lauterburg B.H. Depletion of circulating cyst(e)ine by oral and intravenous mesna. Br J Cancer 68 (1993) 590-593
36. Gulyassy P.F., Jarrard E., and Stanfel L.A. Contributions of hippurate, indoxyl sulfate, and o-hydroxyhippurate to impaired ligand binding by plasma in azotemic humans. Biochem Pharmacol 36 (1987) 4215-4220
37. Keller F., Maiga M., Neumayer H.H., Lode H., and Distler A. Pharmacokinetic effects of altered plasma protein binding of drugs in renal disease. Eur J Drug Metab Pharmacokinet 9 (1984) 275-282
38. Jacobsen D.W., Gatautis V.J., Green R., et al. Rapid HPLC determination of total homocysteine and other thiols in serum and plasma: Sex differences and correlation with cobalamin and folate concentrations in healthy subjects. Clin Chem 40 (1994) 873-881
39. Becker B.N., Himmelfarb J., Henrich W.L., and Hakim R.M. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 8 (1997) 475-486
40. Bostom A.G., and Lathrop L. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 52 (1997) 10-20
41. Smith P.F., Booker B.M., Creaven P., Perez R., and Pendyala L. Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion. J Clin Pharmacol 43 (2003) 1324-1328
42. Friedman A.N., Bostom A.G., Laliberty P., Selhub J., and Shemin D. The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: A randomized, controlled study. Am J Kidney Dis 41 (2003) 442-446
43. Ventura P., Panini R., Abbati G., Marchetti G., and Salvioli G. Urinary and plasma homocysteine and cysteine levels during prolonged oral N-acetylcysteine therapy. Pharmacology 68 (2003) 105-114
44. Elian K.M., and Hoffer L.J. Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease. Metabolism 51 (2002) 881-886
45. Sombolos K., Fragia T., Natse T., et al. The effect of long-term intravenous high dose B-complex vitamins with or without folic acid on serum homocysteine in hemodialysis patients. J Nephrol 15 (2002) 671-675
46. Obeid R., Kuhlmann M.K., Kohler H., and Herrmann W. Response of homocysteine, cystathionine, and methylmalonic acid to vitamin treatment in dialysis patients. Clin Chem 51 (2005) 196-201